BL-1020
- Generic Name
- BL-1020
- Drug Type
- Small Molecule
- Unique Ingredient Identifier
- K1WO7H97QZ
Overview
BL-1020 is a first in class novel compound for the treatment of schizophrenia. It is being developed by BioLineRx (BioLine).
Background
BL-1020 is a first in class novel compound for the treatment of schizophrenia. It is being developed by BioLineRx (BioLine).
Indication
Investigated for use/treatment in schizophrenia and schizoaffective disorders.
Associated Conditions
No associated conditions information available.
Clinical Trials
FDA Approved Products
No FDA products found for this drug
Singapore Approved Products
No Singapore products found for this drug
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath